SRTD Biotech raises €31.5M seed for marker-triggered RNA therapies
Tech Funding News· Sofia Chesnokova·· 8 days agoTop DealsAI Score65
SRTD Biotech raises €31.5M seed for marker-triggered RNA therapies
Why Lilly and Boehringer backed a German startup’s mRNA ‘on-off switch’ in a €31.5M seed
AI Overview
SRTD Biotech, a German startup founded in 2019, raised an oversubscribed €31.5M seed round co-led by Mérieux Equity Partners and NRW.BANK.
Why it matters
The round shows how pharma venture arms are backing RNA designs that activate only in diseased cells, and it sets that against larger US competitors and a flat mRNA market forecast.